Intermittent Fasting Among Overweight and Obese Civil Servants in Malaysia.

September 2, 2021 updated by: Shazana Rifham binti Abdullah, Ministry of Health, Malaysia

Cardiometabolic and Anthropometric Outcomes of Intermittent Fasting Among Overweight and Obese Civil Servants in Malaysia.

This study was a quasi-experimental study established to determine the cardio-metabolic, anthropometric, dietary intake and quality of life changes following combined Intermittent Fasting Healthy Plate and Healthy Plate interventions among overweight and obese civil servants.

Study Overview

Status

Completed

Detailed Description

BACKGROUND

Overweight and obesity among adults is a growing global public health threat and an essential risk factor for various non-communicable diseases. Although it is largely preventable, the worldwide prevalence of obesity nearly tripled from 1975 and 2016 and remained increasing each year. In 2016, more than 1.9 billion adults were overweight, and 650 million were obese. If this current trend continues, it is estimated that 2.7 billion and over 1 billion adults will be overweight and obese by 2025, respectively.

Since obesity occurs due to positive energy balance in the body, the strategies of preventing and treating obesity mainly focus on dietary modification and increasing physical activity. One form of calorie restriction dietary protocol is intermittent fasting (IF), which encompasses various eating diet plans that cycle between a period of fasting and non-fasting over a defined period to create a negative energy balance, hence inducing weight loss. Studies have shown that IF is effective in reducing body weight and improving metabolic outcome. Although the effects of wet IF have been well documented, the benefits of dry IF (except for Ramadan fasting) is not clearly indicated in previous studies. Dry IF is defined as complete fasting without food and fluid intake.

As portion size is a crucial determinant of energy intake, portion control by controlling the serving size is another practical method to reduce calorie intake and promote weight loss. This portion control method has been widely practised and studied worldwide, using different portion divisions depends on the culture and eating habits. Malaysia Healthy Plate, a portion control dietary plan, was created to translate the messages in Malaysia Dietary Guideline 2010 and the Malaysia Food Pyramid 2010. It is a visual tool that emphasises the quarter-quarter-half concept that provides a quick visual technique that helps ensure the intake of food is within the recommended guideline. Specifically, Malaysia Healthy Plate is a single-meal guide that divides the plate into a quarter plate of grains or grains products, a quarter plate of fish, poultry, meat or egg, and a half plate of fruits and vegetables.

While weight losses are reported in studies of conventional IF, the adaptive phenomenon of dry IF on Monday and Thursday on cardiometabolic and anthropometric outcomes is still unclear. Similarly, although the policy of Malaysia Healthy Plate has been widely practised and publicised since 2010, the effectiveness of this eating plan in improving cardiometabolic risks and promoting weight loss is still not well documented. Thus, this study aimed to determine the cardiometabolic, anthropometric, dietary intake and quality of life changes among overweight and obese civil servants following combined Intermittent Fasting and Healthy Plate (IFHP) and Healthy Plate (HP), and to explore the participants' experience throughout the study. The investigators want to investigate whether combining dry IF and HP diet protocol will improve those parameters compared to HP alone.

METHODS

This was a mixed-method quasi-experimental study that evaluates the effectiveness of IFHP and HP among overweight and obese adults. A total of 177 participants were recruited in this study, of which 91 was allocated in the IFHP group and 86 in the HP group. The intervention comprises two phases; supervised (12 weeks) and unsupervised (12 weeks). The data collection was conducted during baseline, after the supervised phase (at week 12), and after the unsupervised phase (at week 24). For each participant, serum and whole blood were collected for analysis. Data on socio-demographic, quality of life, physical activity and dietary intake were also obtained using questionnaires during data collection.

The sample size calculation was conducted using the Power and Sample Size Program. It was followed the rules required for the comparison of two groups (10). The sample size was estimated using the level of significance (α =0.05) and power of the study (1-β=0.80), minimum suggested difference (delta) of 5% weight loss that may be achieved under this intervention and the corresponding differences between groups (SD=10%). The minimum sample size required for the study is 64 participants. By considering 40% attrition, the required sample size for each arm is 90 participants. The total number of participants required for this study is 180.

Data Management

To ascertain that the data collection and record-keeping are conducted efficiently, the Data Collection Booklet was developed and assigned to each participant of this study. This booklet consists of five sections (Socio-demographic, Quality of Life, Physical Activity, Dietary Record and Anthropometry Measurements Sections) sorted into three parts representing each point of data collection; baseline, month three and month six. This booklet was used as a data collection tool to record responses and measurements of the participant during baseline and follow-ups.

Data recorded in the booklet was then entered into a database at the end of the study. The data cleaning procedure was conducted by crosschecking all the entered data in the database and booklet and exploring the data to detect any significant outliers that possibly resulted from measurement error or data entering.

Data Analysis

Analysis was conducted using the Statistical Package of Social Science (SPSS) software version 25 (IBM Corp, NY). Data for continuous variables were presented by mean ± standard deviation (SD) or median and interquartile range (IQR) (for non-normally distributed data). For categorical variables, frequencies were calculated and presented together with percentages. Variables were compared using the independent t-test or Mann-Whitney U test for continuous variables and the Chi-squared or Fisher's exact (n≤5 in any cell) test for categorical variables. All statistical tests were two-sided and used a significance level of p <0.05. In further analysis, the repeated measures ANOVA will be used to compare the within and between groups changes of the outcomes.

Study Type

Interventional

Enrollment (Actual)

177

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kuala Lumpur, Malaysia, 51000
        • Institut Latihan Kementerian Kesihatan Malaysia
      • Kuala Lumpur, Malaysia, 51000
        • Institute for Medical Research
    • Selangor
      • Shah Alam, Selangor, Malaysia, 40170
        • National Institute of Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 59 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • aged 19-59 years
  • BMI of ≥ 23 kg/m2 (overweight or obese)
  • who is ready to participate in the intervention (was assessed through readiness to participate screening)
  • who can provide informed consent.

Exclusion Criteria:

  • has recent involvement in weight loss program/activity (intermittent fasting/diet changes/physical activity changes or any activities that are performed constantly to reduce weight)
  • suffering from any eating disorder
  • was diagnosed with diabetes and hypertension (on medication) or other metabolic health disturbances such as thyroid disease, chronic kidney disease, malignancy and polycystic ovarian syndrome (PCOS)
  • taking any medication or supplements that can affect study outcome
  • pregnant
  • has lack of capacity/language skills to independently follow the protocol were excluded from this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Intermittent Fasting Healthy Plate (IFHP)
Dry fasting from dawn to dusk for two days a week (Monday and Thursday) and Healthy Plate for the rest of the week. Female participants were discouraged from fasting during their menstruation period.
During fasting day, no food or drink allowed from dawn to dusk
Other Names:
  • Dry Intermittent Fasting
Quarter-quarter-half meal concept
Other Names:
  • Malaysian Healthy Plate
ACTIVE_COMPARATOR: Healthy Plate
Practice the Healthy Plate concept in at least one meal every day
Quarter-quarter-half meal concept
Other Names:
  • Malaysian Healthy Plate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body weight changes
Time Frame: Change from Baseline Body Weight at week 12
Body weight changes measured in kilogram
Change from Baseline Body Weight at week 12
Body weight changes
Time Frame: Change from Baseline Body Weight at week 24
Body weight changes measured in kilogram
Change from Baseline Body Weight at week 24
Body mass index (BMI) changes
Time Frame: Change from Baseline BMI at week 12
Body mass index changes measured in kg/m^2 (weight in kilograms, height in meters)
Change from Baseline BMI at week 12
Body mass index (BMI) changes
Time Frame: Change from Baseline BMI at week 24
Body mass index changes measured in kg/m^2 (weight in kilograms, height in meters)
Change from Baseline BMI at week 24
Waist-Hip Ratio (WHR) changes
Time Frame: Change from Baseline WHR at week 12
WHR changes measured in centimeters (waist and hip circumference in centimeters)
Change from Baseline WHR at week 12
Waist-Hip Ratio (WHR) changes
Time Frame: Change from Baseline WHR at week 24
WHR changes measured in centimeters (waist and hip circumference in centimeters)
Change from Baseline WHR at week 24
Body Fat Percentage changes
Time Frame: Change from Baseline Body Fat Percentage at week 12
Body Fat Percentage changes measured in percentage
Change from Baseline Body Fat Percentage at week 12
Body Fat Percentage changes
Time Frame: Change from Baseline Body Fat Percentage at week 24
Body Fat Percentage changes measured in percentage
Change from Baseline Body Fat Percentage at week 24
Body Fat Mass changes
Time Frame: Change from Baseline Body Fat Mass at week 12
Body Fat Mass changes measured in kilograms
Change from Baseline Body Fat Mass at week 12
Body Fat Mass changes
Time Frame: Change from Baseline Body Fat Mass at week 24
Body Fat Mass changes measured in kilograms
Change from Baseline Body Fat Mass at week 24
Fat Free Mass changes
Time Frame: Change from Baseline Body Fat Mass at week 12
Fat Free Mass changes measured in kilograms
Change from Baseline Body Fat Mass at week 12
Fat Free Mass changes
Time Frame: Change from Baseline Body Fat Mass at week 24
Fat Free Mass changes measured in kilograms
Change from Baseline Body Fat Mass at week 24
Systolic Blood Pressure changes
Time Frame: Change from Baseline Systolic Blood Pressure at week 12
Systolic Blood Pressure changes measured in mmHg
Change from Baseline Systolic Blood Pressure at week 12
Systolic Blood Pressure changes
Time Frame: Change from Baseline Systolic Blood Pressure at week 24
Systolic Blood Pressure changes measured in mmHg
Change from Baseline Systolic Blood Pressure at week 24
Diastolic Blood Pressure changes
Time Frame: Change from Baseline Diastolic Blood Pressure at week 12
Diastolic Blood Pressure changes measured in mmHg
Change from Baseline Diastolic Blood Pressure at week 12
Diastolic Blood Pressure changes
Time Frame: Change from Baseline Diastolic Blood Pressure at week 24
Diastolic Blood Pressure changes measured in mmHg
Change from Baseline Diastolic Blood Pressure at week 24
Fasting Blood Glucose changes
Time Frame: Change from Baseline Fasting Blood Glucose at week 12
Fasting Blood Glucose changes measured in mmol/L
Change from Baseline Fasting Blood Glucose at week 12
Fasting Blood Glucose changes
Time Frame: Change from Baseline Fasting Blood Glucose at week 24
Fasting Blood Glucose changes measured in mmol/L
Change from Baseline Fasting Blood Glucose at week 24
2-hour Post Prandial Blood Glucose changes
Time Frame: Change from Baseline 2-hour Post Prandial at week 12
2-hour Post Prandial changes measured in mmol/L
Change from Baseline 2-hour Post Prandial at week 12
2-hour Post Prandial Blood Glucose changes
Time Frame: Change from Baseline 2-hour Post Prandial at week 24
2-hour Post Prandial changes measured in mmol/L
Change from Baseline 2-hour Post Prandial at week 24
HbA1c changes
Time Frame: Change from Baseline HbA1c at week 12
HbA1c changes measured in percentage
Change from Baseline HbA1c at week 12
HbA1c changes
Time Frame: Change from Baseline HbA1c at week 24
HbA1c changes measured in percentage
Change from Baseline HbA1c at week 24
Fasting Total Cholesterol changes
Time Frame: Change from Baseline Fasting Total Cholesterol at week 12
Fasting Total Cholesterol changes measured in mmol/L
Change from Baseline Fasting Total Cholesterol at week 12
Fasting Total Cholesterol changes
Time Frame: Change from Baseline Fasting Total Cholesterol at week 24
Fasting Total Cholesterol changes measured in mmol/L
Change from Baseline Fasting Total Cholesterol at week 24
Fasting Triglyceride changes
Time Frame: Change from Baseline Fasting Triglyceride at week 12
Fasting Triglyceride changes measured in mmol/L
Change from Baseline Fasting Triglyceride at week 12
Fasting Triglyceride changes
Time Frame: Change from Baseline Fasting Triglyceride at week 24
Fasting Triglyceride changes measured in mmol/L
Change from Baseline Fasting Triglyceride at week 24
Fasting High-density Lipoprotein-Cholesterol (HDL-C) changes
Time Frame: Change from Baseline Fasting HDL-C at week 12
Fasting HDL-C measured in mmol/L
Change from Baseline Fasting HDL-C at week 12
Fasting High-density Lipoprotein-Cholesterol (HDL-C) changes
Time Frame: Change from Baseline Fasting HDL-C at week 24
Fasting HDL-C measured in mmol/L
Change from Baseline Fasting HDL-C at week 24
Fasting Low-density Lipoprotein-Cholesterol (LDL-C) changes
Time Frame: Change from Baseline Fasting LDL-C at week 12
Fasting LDL-C measured in mmol/L
Change from Baseline Fasting LDL-C at week 12
Fasting Low-density Lipoprotein-Cholesterol (LDL-C) changes
Time Frame: Change from Baseline Fasting LDL-C at week 24
Fasting LDL-C measured in mmol/L
Change from Baseline Fasting LDL-C at week 24
Fasting Insulin changes
Time Frame: Change from Baseline Fasting Insulin at week 12
Fasting Insulin measured in uU/ml
Change from Baseline Fasting Insulin at week 12
Fasting Insulin changes
Time Frame: Change from Baseline Fasting Insulin at week 24
Fasting Insulin measured in uU/ml
Change from Baseline Fasting Insulin at week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life changes
Time Frame: At baseline, week 12 and week 24
Quality of Life score measured by Obesity and Weight-Loss Quality of Life (OWLQOL ) questionnaire
At baseline, week 12 and week 24
Dietary Intake changes
Time Frame: At baseline, week 12 and week 24
Dietary intake changes measured by Food Frequency Questionnaire (FFQ)
At baseline, week 12 and week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2020

Primary Completion (ACTUAL)

April 7, 2021

Study Completion (ACTUAL)

May 5, 2021

Study Registration Dates

First Submitted

August 23, 2021

First Submitted That Met QC Criteria

August 29, 2021

First Posted (ACTUAL)

September 5, 2021

Study Record Updates

Last Update Posted (ACTUAL)

September 10, 2021

Last Update Submitted That Met QC Criteria

September 2, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NMRR-19-3261-51726

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Intermittent Fasting

Subscribe